Nasus Pharma H1 FY26 net loss widens to $5.94 million
Reuters2026/08/17 12:14- Nasus Pharma posted a net loss of USD 5.9 million for the six months ended June 30, 2026, widening from USD 1.3 million.
- RD expense rose to USD 2.6 million from USD 0.3 million, driven by spending tied to NS002 development.
- GA costs climbed to USD 3.4 million from USD 0.5 million, mainly due to expenses of becoming a public company.
- Cash, cash equivalents and short-term deposits increased to USD 11.9 million from USD 4.3 million, following a USD 15 million private placement.
- Nasus named Brendan P. O’Grady CEO; NS002 pivotal study remains slated for Q4 2026, with topline data expected in Q1 2027.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Euro holds gains above 1.1600 despite robust US jobs data, traders eye ECB rate decision
Port of Tauranga wins fast-track approval for Stella Passage development
The first major "exam" after the Cook era! Morgan Stanley: Apple's (AAPL.US) autumn launch event is the most important in ten years; the first foldable iPhone may spark a new wave of growth
Morgan Stanley analysts stated that Apple's upcoming "Surprise and Shine" autumn product launch event on September 9 may become the company's most important product release in nearly a decade.
Crypto prices
More
